CLINDAGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINDAGEL (CLINDAGEL).
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, disrupting peptide chain initiation. It may also exhibit anti-inflammatory and immunomodulatory effects via inhibition of neutrophil chemotaxis and phagocytosis.
| Metabolism | Hepatic metabolism primarily via CYP3A4. Clindamycin is partially metabolized to active and inactive metabolites. Approximately 10-20% excreted unchanged in urine; remainder as metabolites in bile and feces. |
| Excretion | Approximately 10% of the dose is excreted renally as unchanged drug; the remainder is hepatically metabolized and excreted in bile and feces. Renal clearance accounts for <1% of total clearance. |
| Half-life | 2-3 hours in patients with normal renal function; clinically significant accumulation may occur in severe hepatic impairment. |
| Protein binding | 94% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.2 L/kg; extensive tissue distribution with accumulation in skin, bone, and abscesses. |
| Bioavailability | Oral: 90%; topical: approximately 10% systemically absorbed, minimal systemic exposure. |
| Onset of Action | Topical: 1-2 weeks for initial clinical improvement in acne vulgaris. Oral and parenteral: not applicable for CLINDAGEL. |
| Duration of Action | Sustained release formulation: 12 hours; clinical effect persists for 24 hours after topical application. |
| Molecular Weight | 424.98 |
| Action Class | Lincosamides |
| Brand Substitutes | Clinlup 1% Gel, Ctop 1% Gel, Tocan 1% Gel, Clinderm 1% Gel, Clinzit 1% Gel |
Apply thin layer to affected area twice daily.
| Dosage form | GEL |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific adjustment required. |
| 1st trimester | Clindamycin is generally avoided in the first trimester unless clearly needed; animal studies show no harm but human data are limited. |
| 2nd trimester | Clindamycin is considered safe in the second trimester; systemic absorption minimal after topical application. |
| 3rd trimester | Clindamycin is considered safe in the third trimester; no known risk of preterm labor or neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for CLINDAGEL (CLINDAGEL).
| Placental transfer | Clindamycin crosses the placenta; cord blood levels are approximately 50% of maternal serum levels after oral or IV administration. Topical application likely results in negligible placental transfer due to minimal systemic absorption. |
| Breastfeeding | Clindamycin is excreted into breast milk in small amounts after topical application, with infant dose estimated at <0.1% of maternal weight-adjusted dose; not expected to cause adverse effects in breastfed infants. However, monitor for gastrointestinal disturbances (e.g., diarrhea, bloody stools) as rare cases of Clostridium difficile colitis have been reported in infants exposed via breast milk. |
■ FDA Black Box Warning
Clindamycin can cause severe colitis, which may be fatal. Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
| Serious Effects |
Hypersensitivity to clindamycin or lincomycinHistory of clindamycin-associated colitis (Clostridium difficile infection)
| Precautions | Clostridium difficile-associated diarrhea (CDAD) risk, Hypersensitivity reactions including anaphylaxis, Use with caution in patients with history of gastrointestinal disease, particularly colitis, Potential for overgrowth of nonsusceptible organisms, including fungi, Neuromuscular blocking effects may enhance action of other neuromuscular blocking agents |
| Food/Dietary | No clinically significant food interactions reported for topical clindamycin. Oral absorption is not relevant for topical use. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects observed at doses up to 5 times human dose. Potential fetal risk unknown. Use only if clearly needed. |
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | No data on fertility effects in humans. Animal studies show no impairment of fertility. |
| Clinical Pearls | Topical clindamycin is a lincosamide antibiotic used for acne vulgaris. It can cause pseudomembranous colitis even with topical use; discontinue if diarrhea occurs. Avoid concurrent use with erythromycin due to antagonism. Apply thin film to affected areas; overuse increases irritation risk. Use with benzoyl peroxide to reduce bacterial resistance. |
| Patient Advice | Apply a thin layer to affected skin areas only, avoiding eyes, mouth, and mucous membranes. · Wash hands before and after application unless treating hands. · Do not use more or less often than prescribed; overuse may cause skin irritation. · Avoid contact with abrasive or medicated soaps and cosmetics unless approved by your doctor. · Inform your doctor if you develop severe diarrhea, abdominal cramps, or bloody stools; this may indicate colitis. · Keep medication away from open flames or heat; it is flammable. · Do not share this medication with others. |